Canada’s Biotech Valley of Death Is About More Than Capital

Canada has a well-documented growth-capital gap: the risky stretch between roughly $5 million and $25 million where promising companies struggle to move from validation to scale. As The Globe and Mail recently reported, this gap is not simply a shortage of programs or public dollars. Ottawa already spends roughly $ 4.5billion a year across more than 130 programs to support  innovative companies. The problem is that this support remains fragmented and only weakly connected to the evidence companies need to become financeable when larger, more specialized capital is required. 

That weak connection matters because it is coupled with a credibility-translation challenge. Because of this second credibility-translation gap,  scientific progress, mission and early traction fail to turn into credible proof points that investors can use to judge execution, scalability and commercial readiness. Translation and credibility matter as companies move from early validation to scale, when the evidence investors need becomes more specialized and the consequences of misreading readiness become more costly. 

This is especially evident in biotechnology. Investors are not simply assessing growth, they must also assess whether complex science can be translated into a financeable path for development, approval, adoption, and scale. A company may have strong science and a compelling mission yet still fail to appear ready for the next stage of financing. 

My doctoral research, which included Canadian and U.S. biotechnology firms, suggests that this credibility-translation challenge is not uniquely Canadian. It is a structural feature of biotech commercialization. Science-based ventures must ask investors to evaluate long timelines, regulatory uncertainty, clinical evidence, reimbursement pathways, capital intensity, and mission driven commitments all at once. 

A company’s purpose can build trust with patients, clinicians, regulators and potential partners.  But mission becomes credible to investors only when it is tied to staged, evidence generation plans, governance, regulatory strategy, and a clear capital plan. 

Canada’s challenge is that this broader biotech translation problem collides with a thinner  domestic market for growth capital. Canadian Venture Capital and Private Equity Association (CVCA) data show that Canadian capital is present early but declines as venture rounds get larger. In 2024, Canadian-only syndicates accounted for 70.4 per cent of the investment value in rounds under $5 million, but only 12.7 per cent in rounds over $50 million. In other words, Canadian capital is active at formation but much less likely to lead when companies need larger scale-up rounds. 

The pattern is sharper in life sciences and therapeutics. adMare data show that domestic investor participation in Canadian therapeutics falls from 42 per cent at start-up to 24 per cent at late stage. For therapeutics deals over $50 million, international investors account for 76 per cent of investors  and 67 per cent of deal volume. Meanwhile, CPE Analytics reported that life science/biotech investment fell from 26 per cent to 16 per cent of Canadian venture investment in 2025, with total dollars invested down 40 per cent.

Foreign capital is not problematic itself; in many cases, it may be essential. However, when Canadian firms are not able to consistently find scale validation and lead capital in the domestic market, these numbers may point to a transition problem. Canadian life sciences  companies can form, attract early support, and generate promising science. Still, as their capital  needs grow, they often need to prove their readiness to larger, more specialized and frequently  foreign investors.  

That is where policy needs to evolve. Canada should not only fund innovation. It should help more firms generate and communicate the evidence, governance, regulatory strategy, and  commercialization milestones that later-stage investors require. Otherwise, companies will  continue to reach the scaling stage before domestic capital is ready to participate with confidence.  

Canada’s valley of death is often described as a financing gap, but money is only part of the  problem. The valley also exists where scientific promise has not yet been translated into an  investment case that domestic capital can act on. Until Canada addresses both capital depth and credibility translation, too many promising companies will build value here only to realize it  elsewhere.